176 related articles for article (PubMed ID: 38385031)
1. Neurological involvement among non-hospitalized adolescents and young adults 6 months after acute COVID-19.
Havdal LB; Selvakumar J; Lund Berven L; Stiansen-Sonerud T; Zetterberg H; Blennow K; Holmøy T; Wyller VBB
Front Neurol; 2024; 15():1345787. PubMed ID: 38385031
[TBL] [Abstract][Full Text] [Related]
2. Neurological Involvement in COVID-19 Among Non-Hospitalized Adolescents and Young Adults.
Havdal LB; Berven LL; Selvakumar J; Stiansen-Sonerud T; Leegaard TM; Tjade T; Zetterberg H; Blennow K; Wyller VBB
Front Neurol; 2022; 13():915712. PubMed ID: 35812102
[TBL] [Abstract][Full Text] [Related]
3. Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up.
Kanberg N; Simrén J; Edén A; Andersson LM; Nilsson S; Ashton NJ; Sundvall PD; Nellgård B; Blennow K; Zetterberg H; Gisslén M
EBioMedicine; 2021 Aug; 70():103512. PubMed ID: 34333238
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID-19 and associated with neurological symptoms and disease severity.
Virhammar J; Nääs A; Fällmar D; Cunningham JL; Klang A; Ashton NJ; Jackmann S; Westman G; Frithiof R; Blennow K; Zetterberg H; Kumlien E; Rostami E
Eur J Neurol; 2021 Oct; 28(10):3324-3331. PubMed ID: 33369818
[TBL] [Abstract][Full Text] [Related]
5. Transient Changes in the Plasma of Astrocytic and Neuronal Injury Biomarkers in COVID-19 Patients without Neurological Syndromes.
Lennol MP; Ashton NJ; Moreno-Pérez O; García-Ayllón MS; Ramos-Rincon JM; Andrés M; León-Ramírez JM; Boix V; Gil J; Blennow K; Merino E; Zetterberg H; Sáez-Valero J
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769057
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and Characteristics Associated With Post-COVID-19 Condition Among Nonhospitalized Adolescents and Young Adults.
Selvakumar J; Havdal LB; Drevvatne M; Brodwall EM; Lund Berven L; Stiansen-Sonerud T; Einvik G; Leegaard TM; Tjade T; Michelsen AE; Mollnes TE; Lund-Johansen F; Holmøy T; Zetterberg H; Blennow K; Sandler CX; Cvejic E; Lloyd AR; Wyller VBB
JAMA Netw Open; 2023 Mar; 6(3):e235763. PubMed ID: 36995712
[TBL] [Abstract][Full Text] [Related]
7. Association of serum neurofilament light chain and glial fibrillary acidic protein levels with cognitive decline in Parkinson's disease.
Mao S; Teng X; Li Z; Zu J; Zhang T; Xu C; Cui G
Brain Res; 2023 Apr; 1805():148271. PubMed ID: 36754139
[TBL] [Abstract][Full Text] [Related]
8. Blood neurofilament light concentration at admittance: a potential prognostic marker in COVID-19.
Aamodt AH; Høgestøl EA; Popperud TH; Holter JC; Dyrhol-Riise AM; Tonby K; Stiksrud B; Quist-Paulsen E; Berge T; Barratt-Due A; Aukrust P; Heggelund L; Blennow K; Zetterberg H; Harbo HF
J Neurol; 2021 Oct; 268(10):3574-3583. PubMed ID: 33743046
[TBL] [Abstract][Full Text] [Related]
9. Serum Tau, Neurofilament Light Chain, Glial Fibrillary Acidic Protein, and Ubiquitin Carboxyl-Terminal Hydrolase L1 Are Associated with the Chronic Deterioration of Neurobehavioral Symptoms after Traumatic Brain Injury.
Lange RT; Lippa S; Brickell TA; Gill J; French LM
J Neurotrauma; 2023 Mar; 40(5-6):482-492. PubMed ID: 36170576
[TBL] [Abstract][Full Text] [Related]
10. Concentrations of Serum Brain Injury Biomarkers Following SARS-CoV-2 Infection in Individuals with and without Long-COVID-Results from the Prospective Population-Based COVI-GAPP Study.
Telser J; Grossmann K; Weideli OC; Hillmann D; Aeschbacher S; Wohlwend N; Velez L; Kuhle J; Maleska A; Benkert P; Risch C; Conen D; Risch M; Risch L
Diagnostics (Basel); 2023 Jun; 13(13):. PubMed ID: 37443561
[TBL] [Abstract][Full Text] [Related]
11. Serum GFAP, NfL, and tau concentrations are associated with worse neurobehavioral functioning following mild, moderate, and severe TBI: a cross-sectional multiple-cohort study.
Edwards KA; Lange RT; Lippa SM; Brickell TA; Gill JM; French LM
Front Neurol; 2023; 14():1223960. PubMed ID: 38292036
[TBL] [Abstract][Full Text] [Related]
12. High Levels of NfL, GFAP, TAU, and UCH-L1 as Potential Predictor Biomarkers of Severity and Lethality in Acute COVID-19.
Salvio AL; Fernandes RA; Ferreira HFA; Duarte LA; Gutman EG; Raposo-Vedovi JV; Filho CHFR; da Costa Nunes Pimentel Coelho WL; Passos GF; Andraus MEC; da Costa Gonçalves JP; Cavalcanti MG; Amaro MP; Kader R; de Andrade Medronho R; Figueiredo CP; Amado-Leon LA; Alves-Leon SV
Mol Neurobiol; 2024 Jun; 61(6):3545-3558. PubMed ID: 37996731
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers of Neurological Damage: From Acute Stage to Post-Acute Sequelae of COVID-19.
Zingaropoli MA; Pasculli P; Barbato C; Petrella C; Fiore M; Dominelli F; Latronico T; Ciccone F; Antonacci M; Liuzzi GM; Talarico G; Bruno G; Galardo G; Pugliese F; Lichtner M; Mastroianni CM; Minni A; Ciardi MR
Cells; 2023 Sep; 12(18):. PubMed ID: 37759493
[No Abstract] [Full Text] [Related]
14. Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study.
Verberk IMW; Laarhuis MB; van den Bosch KA; Ebenau JL; van Leeuwenstijn M; Prins ND; Scheltens P; Teunissen CE; van der Flier WM
Lancet Healthy Longev; 2021 Feb; 2(2):e87-e95. PubMed ID: 36098162
[TBL] [Abstract][Full Text] [Related]
15. Plasma Markers of Neurologic Injury and Inflammation in People With Self-Reported Neurologic Postacute Sequelae of SARS-CoV-2 Infection.
Peluso MJ; Sans HM; Forman CA; Nylander AN; Ho HE; Lu S; Goldberg SA; Hoh R; Tai V; Munter SE; Chenna A; Yee BC; Winslow JW; Petropoulos CJ; Martin JN; Kelly JD; Durstenfeld MS; Hsue PY; Hunt PW; Greene M; Chow FC; Hellmuth J; Henrich TJ; Glidden DV; Deeks SG
Neurol Neuroimmunol Neuroinflamm; 2022 Sep; 9(5):. PubMed ID: 35701186
[TBL] [Abstract][Full Text] [Related]
16. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
[TBL] [Abstract][Full Text] [Related]
17. Serum glial fibrillary acidic protein and neurofilament light chain in treatment-naïve patients with unipolar depression.
Hviid CVB; Benros ME; Krogh J; Nordentoft M; Christensen SH
J Affect Disord; 2023 Oct; 338():341-348. PubMed ID: 37336248
[TBL] [Abstract][Full Text] [Related]
18. Central nervous system biomarkers GFAp and NfL associate with post-acute cognitive impairment and fatigue following critical COVID-19.
Bark L; Larsson IM; Wallin E; Simrén J; Zetterberg H; Lipcsey M; Frithiof R; Rostami E; Hultström M
Sci Rep; 2023 Aug; 13(1):13144. PubMed ID: 37573366
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory markers and pulmonary function in adolescents and young adults 6 months after mild COVID-19.
Sommen SL; Havdal LB; Selvakumar J; Einvik G; Leegaard TM; Lund-Johansen F; Michelsen AE; Mollnes TE; Stiansen-Sonerud T; Tjade T; Wyller VBB; Berven LL
Front Immunol; 2022; 13():1081718. PubMed ID: 36685555
[TBL] [Abstract][Full Text] [Related]
20. The relationship between serum neurofilament light chain and glial fibrillary acidic protein with the REM sleep behavior disorder subtype of Parkinson's disease.
Teng X; Mao S; Wu H; Shao Q; Zu J; Zhang W; Zhou S; Zhang T; Zhu J; Cui G; Xu C
J Neurochem; 2023 Apr; 165(2):268-276. PubMed ID: 36776136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
